Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis

Hye Seon Kim 1, Jong Bae Park 2, Ho-Shin Gwak 3*, Ji-Woong Kwon 4, Sang-Hoon Shin 4 and Heon Yoo 4

Abstract

Background: Leptomeningeal carcinomatosis (LMC) is frequently associated with hydrocephalus, which quickly devastates the performance of the patient. Cerebrospinal fluid (CSF) shunt is a widely accepted treatment of choice, but the clinical outcomes in patients with LMC are not well studied. This study aimed to examine the efficacy of a CSF shunt in patients with LMC.

Methods: Seventy patients with LMC confirmed by cytology or magnetic resonance imaging (MRI) underwent ventriculoperitoneal (VP) or lumboperitoneal (LP) shunt surgery. We retrospectively analyzed the clinical characteristics of patients, symptom improvement after the shunt, rate of complications associated with the surgery, and overall survival.

Results: Fifty-five patients had systemic cancer as a preceding disease, including lung cancer (45), breast cancer (6), and others (4). Primary brain tumors were mainly glioma (7) and medulloblastoma (5). Fifty-one patients had VP shunt, and 19 had LP shunt. After surgery, preoperative symptoms “improved” in 35 patients (50%) and were “normalized” in 24 of those patients (34%). Shunt malfunction occurred in eight patients, and infection occurred in eight patients. Seventeen patients underwent revision due to infection, shunt malfunction, or over-drainage. There were no complications associated with peritoneal seeding during a median follow-up of 3.3 months after surgery. The median overall survival was 8.7 months (95% confidence interval, 6.0–11.4) from LMC diagnosis and 4.1 months from shunt surgery.

Conclusion: VP or LP shunt is effective for patients with hydrocephalus from LMC in terms of symptom improvement and prolonging of overall survival with an acceptable rate of procedure-related complications.

Trial registration: This study was approved by the Institutional Review Board (IRB) of the National Cancer Center (retrospectively registered, NCC2018-0051).

Keywords: Cerebrospinal fluid, Complication, Efficacy, Leptomeningeal carcinomatosis, Shunt

Background

Leptomeningeal carcinomatosis (LMC), a terminal disease defined by spreading of cancer cells in the cerebrospinal fluid (CSF), affects 5–10% of patients with solid tumors, and the most notorious of which are melanoma; breast, lung, and ovarian cancers; and primary brain tumors [1].

LMC has a poor prognosis as the life expectancy after diagnosis is 4–6 weeks without treatment [1, 2]. LMC is challenging to treat in many ways. Radiation to local field has a limited role, as the disease is disseminated along the neuraxis [3]. Systemic chemotherapy is ineffective because of the blood-brain barrier [4]. Intra-CSF chemotherapy, administered either intrathecally or intra-ventriculally, can maintain therapeutic drug concentrations in the CSF for 48–72 h [5]; however, a marginal survival benefit of 3–6 months and suspicious neurotoxicity raise questions about its effectiveness [6–8].
Infiltration of the CSF space by cancer cells may obstruct CSF pathways and cause CSF malabsorption, resulting in increased intracranial pressure (ICP) and/or hydrocephalus [9]. The common presenting symptoms of LMC include headache, nausea, vomiting, and altered mentality, all of which are related to increased ICP and hydrocephalus. Increased ICP causes an uneven distribution of intrathecally or intraventricularly administered drugs, making them less effective [10]. Thus, hydrocephalus and increased ICP degrade the performance and prognosis of patients with LMC.

Although CSF shunt surgery is a relatively simple neurosurgical procedure, the percentage of patients who receive it is less than the incidence of increased ICP; and its outcomes are little and rarely reported [11–13]. As the prognoses of patients with LMC are poor, there is a tendency for physicians to decline aggressive treatment such as surgical intervention. Furthermore, complications such as hemorrhage, infection, and device malfunction, along with the risk of peritoneal transfer of cancer cells, are reasons to not perform CSF shunt in patients with LMC [14, 15].

This retrospective study aimed to evaluate the efficacy of CSF shunt in patients with LMC in terms of (1) symptom improvement, (2) malfunction rate, including cancer cell–caused obstruction or spillage, and (3) overall survival (OS) benefit.

**Methods**

**Study design**

This retrospective review was based on the electronic medical records of 70 consecutive patients that underwent placement of either ventriculoperitoneal (VP) or lumboperitoneal (LP) shunt for treatment of increased ICP or hydrocephalus secondary to LMC between 2002 and 2017 at a single institution, National Cancer Center, Korea. All patients were diagnosed by CSF cytology and had a suggestive or definite finding of LMC [16] on gadolinium-enhanced MRI. This retrospective study was reviewed and approved by the Institutional Review Board of the National Cancer Center of Korea (NCC2018-0043).

**Clinical parameters and operative procedures**

Demographic data, primary tumor type, preoperative Karnofsky performance status (KPS) score, and type of the shunt (VP vs. LP) were analyzed as possible factors affecting the shunt results. Shunt procedures were performed routinely as described in the literature [13]. The operating physicians chose the type of shunt and entry point (in case of VP shunt). The type of reservoir (fixed vs. programmable) was determined based on the availability or ICP.

**End points**

Symptom improvement was evaluated at the time patients were discharged from the hospital after shunt surgery and defined as follows: (1) “normalized,” all hydrocephalus–related symptoms were clearly solved; (2) “improved,” preoperative hydrocephalus–related symptoms were improved but remained to some extent; (3) “not improved,” preoperative hydrocephalus–related symptoms were unchanged. Complications were classified as malfunctions or CSF infections that lead to shunt revision. Causes of malfunctions were confirmed either by a shunt function test or by intraoperative findings.

Survival time was calculated from either the date of LMC diagnosis or the day of shunt placement until death or last follow-up visit.

**Statistical analysis**

Parameters were analyzed using the Statistical Package for Social Sciences (SPSS, version 18, Chicago, IL). Categorical variables were compared between the VP shunt and LP shunt using the chi-square test. A \( p<0.05 \) indicated statistical significance. A Kaplan-Meier curve was used to analyze survival rates, and a log-rank test was used to evaluate prognostic factors associated with OS.

**Results**

**Patient characteristics**

Seventy patients (40 females, 30 males) underwent shunt operation during the study period. All patients had extraventricular drainage or lumbar drainage to control increased intracranial pressure or to relieve headache before the shunt procedure. Disease preceding LMC was systemic cancer in 55 patients and primary brain tumors in 15 patients (Table 1). The systemic cancers were non-small cell lung cancer (NSCLC; \( n=45 \)), breast cancer (\( n=6 \)), leukemia (\( n=2 \)), cholangiocarcinoma (\( n=1 \)), and malignancy of unknown origin (\( n=1 \)). The primary brain tumors were high-grade glioma (\( n=7 \)), medulloblastoma (\( n=5 \)), primary neuroectodermal tumor (\( n=2 \)), and atypical teratoid/rhabdoid tumor (\( n=1 \)).

The median age of the patients was 53 (range, 1–81) years. Patients with primary brain tumors had lower median age than those with systemic cancers (18.0 vs. 56.0 years, \( p<0.001 \)). The median preoperative KPS score was 70 (range, 40–90).

**Clinical outcomes after surgery**

Fifty-one and 19 patients underwent VP shunt and LP shunt, respectively. There was no predilection for shunt type according to preceding disease. Forty-six patients (92%) with VP shunts and 13 patients (68%) with LP shunts had a programmable valve [that difference was because of late availability of programmable valves for LP shunt (since 2012)].
After shunt surgery, preoperative symptoms were “normalized” in 24 patients (34%), “improved” in 35 patients (50%), and “not improved” in 11 patients (16%). The type of shunt used (VP vs. LP), preceding disease (systemic metastases vs. primary brain tumor), and preoperative KPS score (≥70 vs. <70) did not affect the clinical outcomes.

Complications related to the shunt procedure
Median follow-up time was 3.3 (range, 0.2–43.0; 95% confidence interval, 3.47–6.93) months after the shunt. Neither peritoneal seeding nor secondary ascites were observed in all patients during the follow-up period. Seventeen patients (24%) underwent revision surgery due to malfunction or infection (eight patients each) or to intolerable over-drainage symptoms (one patient, case 17, Table 2). The average time between initial surgery and revision surgery was 1.1 ± 0.86 months. Six patients required a second revision surgery, and two needed a third revision.

Infections leading to revision surgery were due to skin contaminants in six patients, four of which had Staphylococcus epidermidis infection and a history of methotrexate intraventricular injection via Ommaya reservoir in the presence of LP shunt (cases 2, 3, 4, and 7). The other two patients had VP shunts and had Staphylococcus aureus infection at 1 month and 6 months after the shunt surgery, respectively, without any history of reservoir puncture before the infection (one patient, case 17, Table 2). The average time between initial surgery and revision surgery was 1.1 ± 0.86 months. Six patients required a second revision surgery, and two needed a third revision.

Shunt malfunction occurred in eight patients. In four patients, shunt function study documented the malfunction site. Two patients with VP shunts and glioblastoma (case 9) and medulloblastoma (case 10) showed distal and ventricular catheter obstruction, respectively. No cancer cell obstruction but only myxoid material was found in the ventricular catheter from the patient with medulloblastoma. Two patients with LP shunts with fixed pressure-valve reservoirs had proximal catheter obstruction (case 14) and distal catheter leakage at the junction with the reservoir (case 16), respectively. In another two patients, X-ray examination revealed mechanical failures due to proximal catheter migration (case 11) and distal catheter malposition into the pre-peritoneal space (case 13), respectively. The remaining two patients had LP shunts with fixed pressure-valve reservoirs. Under-drainage was suspected in those patients because of deterioration before revision, although neither obstruction nor malfunction was found during revision surgery. One patient received a VP replacement shunt (case 12), and the other received an intraventricular Ommaya (case 15).

Revision surgery was more common in patients with LP shunts than in those with VP shunts because of the higher rates of malfunction (5/14 vs. 3/48, p = 0.017) and infection (2/49 vs. 6/13, p < 0.001) with the LP shunts. Five out of seven LP shunts with fixed pressure-valve reservoirs malfunctioned, while all 12 LP shunts with programmable valves did not. A possible reason for the higher incidence of infection in the patients with LP shunts is that four out of 11 patients that received Ommaya intraventricular chemotherapy had S. epidermidis infection.

Five patients had medulloblastoma, and none of them showed any sign of peritoneal seeding during 2.9–40.3 months of follow-up.

Overall survival
Fifty-six patients (80%) died during follow-up, 27 (48%) because of LMC progression and 13 (23%)
because of systemic disease progression. The cause of death was undetermined in 16 patients (29%). The median survival of all patients was 8.7 months (range, 0.2–52; 95% confidence interval (CI), 6.0–11.4; Fig. 1) after LMC diagnosis and 3.9 months (95% CI, 2.6–5.2) after initial shunt surgery.

Patients with LMC from systemic cancer had significantly shorter OS than patients with primary brain tumors (7.6 vs. 13.9 months, \( p = 0.03, \) Fig. 1b). Patients with breast cancer had longer OS than patients with NSCLC (17.2 vs. 7.6 months, \( p = 0.044 \)).

The OS of patients with LMC from NSCLC (n = 45) was compared to patients from another set of patients (n = 46) with LMC from NSCLC who had increased ICP and received intraventricular chemotherapy (n = 105) but did not receive shunts in a historical data [17]. The OS of NSCLC patients with the shunt (7.6 months; 95% CI, 5.8–9.4) was significantly prolonged compared to that of NSCLC patients without the shunt (2.3 months; 95% CI, 1.6–3.0) (\( p < 0.001, \) Fig. 2).

**Discussion**

Despite the poor prognosis associated with LMC, CSF shunting to treat hydrocephalus or increased ICP significantly attenuated symptoms and prolonged OS in this study.

**Effectiveness of CSF shunt in patients with LMC**

Most studies reporting clinical results of CSF shunts in patients with LMC have focused on the analysis of LMC or CNS metastases, and few patients with those conditions receive shunt procedures [11, 18]. Omuro et al. [19] reviewed the outcomes of 37 patients with LMC from systemic cancer (excluding primary brain tumors) that received VP shunt for increased ICP and reported improvement of ICP-related symptoms in 27 patients (77%). Lee et al. [13] reported a similar improvement rate of 80% after VP shunt in patients with CNS metastases (40 patients with LMC and 10 patients with parenchymal brain metastases), noting improvement of headache (86% of patients), gait disturbance (71% of patients), cognitive dysfunction (40% of patients), and urinary incontinence (40% of patients). In

---

**Table 2** Description of shunt revision due to malfunction and infection

| Case no. | Sex/age | Primary ca. | Shunt type/reservoir | Malfunction or infection | Revision |
|----------|---------|-------------|----------------------|--------------------------|----------|
| 1        | M/34    | NSCLC       | VP/programmable      | S. aureus infection presented as malfunction with pus discharge around the distal catheter at 1 month | Shunt removal |
| 2        | F/61    | Breast ca.  | LP/programmable      | S. epidermidis infection after Ommaya MTX injection | Shunt removal and VP shunt 2 months later |
| 3        | F/56    | Breast ca.  | LP/programmable      | S. epidermidis infection after Ommaya MTX injection | Shunt removal, lumbar drainage, and re-insertion after infection control |
| 4        | F/61    | NSCLC       | LP/programmable      | Wound dehiscence after Ommaya MTX injection resulted in S. epidermidis infection | Shunt removal, extraventricular drainage, and re-insertion after infection control |
| 5        | F/63    | NSCLC       | LP/programmable      | K. pneumoniae infection 4 days after the shunt | Shunt removal and extraventricular drainage |
| 6        | F/59    | NSCLC       | LP/programmable      | C. albicans infection of abdominal wound | Shunt removal and VP shunt |
| 7        | F/18    | MBL         | LP/programmable      | S. epidermidis infection after Ommaya MTX injection | Shunt removal and re-insertion after infection control |
| 8        | F/59    | NSCLC       | VP/programmable      | S. aureus infection 6 months after the shunt | Shunt removal |
| 9        | F/29    | GBL         | VP/programmable      | Distal catheter obstruction 3 months after the shunt | Distal catheter externalization |
| 10       | F/13    | MBL         | VP/programmable      | Ventricular catheter obstruction (myxoid material only) | Extraventricular drainage and re-insertion |
| 11       | M/1     | MBL         | VP/programmable      | Proximal catheter migration on 10 days after the shunt | Shunt revision |
| 12       | M/74    | NSCLC       | LP/fixed             | Under-drainage without obstruction | Catheter irrigation and VP shunt later |
| 13       | F/52    | NSCLC       | LP/fixed             | Distal catheter (pre-peritoneal) malposition | Distal wound revision |
| 14       | M/52    | NSCLC       | LP/fixed             | Proximal catheter obstruction | LP shunt removal and VP shunt |
| 15       | M/54    | NSCLC       | LP/fixed             | Under-drainage without obstruction | LP shunt removal and ventricular Ommaya |
| 16       | M/53    | AOG         | LP/fixed             | Distal catheter leakage with reservoir | LP shunt removal and VP shunt |
| 17       | F/8     | MBL         | VP/fixed             | Intolerable over-drainage | Revision with programmable valve |

**Abbreviations:** AOG anaplastic oligodendroglioma, GBL glioblastoma, LP lumboperitoneal, MBL medulloblastoma, MTX methotrexate, NSCLC non-small cell lung cancer, VP ventriculoperitoneal
Fig. 1 Overall survival (OS) of patients who received CSF shunts due to hydrocephalus from leptomeningeal carcinomatosis (a). OS according to preceding disease of brain metastases and primary brain tumors (b) (n = 70)

Fig. 2 Comparison of overall survival time of patients with non-small cell lung cancer that received shunt surgery (n = 45) versus that of patients with non-small cell lung cancer that did not receive shunt surgery but received conventional intraventricular chemotherapy (n = 101; data published in J Thorac Oncol, 2013 [17])
the present study, 59 patients (84%) had improvement of preoperative symptoms, including 24 patients (34%) whose condition was “normalized.” Future studies will need to differentiate between symptoms caused by hydrocephalus and those caused by LMC (e.g., altered mentality) or brain tumors, in case of accompanying parenchymal mass lesions.

Despite the improvements in symptoms, some shunt surgeries resulted in revisions due to malfunction or infection. Complication rates following shunt procedures vary from 4 to 85% according to the shunt type (VP vs. LP), procedure (freehand vs. stereotactic), valve type (programmable vs. fixed), or chronology [20–23]. In a nation-wide (the USA) study of revision rates after shunt surgery in 4480 patients with idiopathic intracranial hypertension from 2005 to 2009, Menger et al. reported that 3.9% of VP shunts and 7.0% of LP shunts (p < 0.0001) required revision [15]. The revision rate in patients with LMC appears to be higher than those figures. In this study, LP shunts with fixed pressure-valve reservoirs had the highest revision rate (5 out of 7) among the shunt and reservoir types; VP shunts malfunctioned in three out of 51 patients (5.9%). Omuro et al., who used only VP shunts for patients with LMC, reported that 8% of the shunts malfunctioned and required revision surgery. Neither the present study nor that of Omuro et al. found cancer cell obstruction of the shunt tubing or the reservoir. Another dangerous potential complication of CSF shunts is peritoneal seeding of cancer cells. To date, the documented cases of such seeding are mostly from medulloblastomas, which are well known to cause extra-neural metastases [14, 24, 25]. In those cases, the shunt was inserted before or after tumor removal, and peritoneal seeding occurred with or without primary tumor recurrence. Although the five patients with medulloblastoma in the present study had no documented shunt-mediated metastasis, such metastasis has been diagnosed up to 5 years after shunt placement [25].

**Overall survival after the shunt**

VP shunt has been suggested to relieve increased ICP and to improve the OS of patients with LMC [6, 9, 11]. Omuro et al. reported median OS among 37 patients with LMC from systemic cancer as 2 months after the shunt and 4 months after diagnosis of LMC (range, 2 days to 3.6 years) [19]. Jung et al. reported that patients with LMC and hydrocephalus that received surgical treatment had longer OS than those that did not receive surgical treatment (5.7 months vs. 1.7 months), although the difference was not statistically significant because of the small numbers of patients (n = 7 and 11, respectively) [11]. In the present study, patients with LMC from systemic cancer showed a median OS of 7.6 months after diagnosis.

**Appropriate shunt types in patients with LMC**

Both VP and LP shunting could safely divert CSF flow either from a ventricle or spinal arachnoid space to peritoneal space. Each type of shunt system has advantages and disadvantages, so the choice should be tailored to the patient’s condition. In general, LP shunting is confined to communicating hydrocephalus (HCP) and preferentially used in patients who are not suitable for cranial surgery (i.e., idiopathic intracranial hypertension with slit ventricle) or who want to avoid cranial surgery, whereas VP shunting can be used regardless of communicating or non-communicating HCP [15, 26]. Earlier-era LP shunts without adjustable valve reservoirs had problems in adjusting the amount of CSF drainage and assessing the shunt patency [27, 28]. Hence, LP shunts have been less frequently used than VP shunts. Those problems are much reduced since the advent of LP shunts with programmable valve reservoirs [29]. In the present study, all mechanical malfunctions of LP shunts occurred with the fixed-valve reservoir type; LP shunts with programmable valve reservoirs had revisions due only to infection.

Continuing intraventricular chemotherapy was tried in patients with LMC and a shunt. For those with VP shunt, CSF is directly drained into the peritoneal space from the ventricle, and therefore, a drug delivered intraventricularly would be mainly carried not into lumbar/cisternal CSF space but into the peritoneal space. To overcome this problem, on-off valve system had been tried in other studies for the purpose of enforcing drug delivery to lumbar/cisternal CSF space by closing the shunt [30]. However, we still have not had pharmacokinetic data that showed how much of the intraventricularly injected drug reached lumbar/cisternal CSF space during valve-off time in these patients who lost their physiologic CSF flow unless they injected the drug via lumbar puncture. In this study, we used a combination of Ommaya reservoir and LP shunt. Previously, this concurrent use of Ommaya reservoir and LP shunt was studied for the access to CSF space in the era of LP shunt without reservoir valve system. Zhang et al. reviewed the LP shunting in patients with LMC and suggested a hypothetical advantage of cooperative use of Ommaya reservoirs [31]. Eleven patients in the present study received an LP shunt in addition to a pre-installed Ommaya reservoir for the purpose of intraventricular chemotherapy. We measured lumbar methotrexate level from LP shunt reservoir in a patient and evaluated therapeutic concentration was achieved at approximated half-time of 2.3–4.2 h (data not provided). Four of those patients contracted *S. epidermidis* infections after intraventricular chemotherapy injection. Recent improvements in aseptic techniques of intraventricular chemotherapy injection have so far resulted in no further CSF infections in our institution.
**Conclusion**

Patients with LMC and increased ICP or hydrocephalus benefit from CSF shunt in terms of symptom alleviation and survival. Although shunt malfunctions and infections may occur, careful aseptic technique and sophisticated programmable valve systems decrease the procedure-related complications.

**Abbreviations**

CSF: Cerebrospinal fluid; HCP: Hydrocephalus; ICP: Intracranial pressure; KPS: Kadosky performance status; LMC: Leptomeningeal carcinomatosis; LP: Lumboperitoneal; NSCLC: Non-small cell lung cancer; OS: Overall survival; VP: Ventriculoperitoneal.

**Acknowledgements**

Not applicable

**Funding**

This work was supported by grants from National Cancer Center, Korea (1710871-2, 1810212-3), and a grant of the Korea Health Industry Development Institute, funded by the Ministry of Health & welfare, Republic of Korea (grant no: H17C1018).

**Availability of data and materials**

The dataset analyzed in this study is available from the corresponding author upon request and with permission of ethics committee of National Cancer Center, Korea.

**Authors’ contributions**

HSK analyzed the data. H-SG and JBP supervised the work. H-SG, J-WK, S-HS, and HY participated in the treatment. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board (IRB) of National Cancer Center, Goyang, Republic of Korea. 4Neuro-oncology Clinic, National Cancer Center, Graduate School of Cancer Science and Policy, National Cancer Center, Korea.

**Consenst for publication**

Not applicable

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea. 2. Department of Biomedical Science, National Cancer Center, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea. 3. Department of Cancer Control, National Cancer Center, Graduate School of Cancer Science and Policy, National Cancer Center, 323 Ilsan-ro, Ilsan-dong-gu, Goyang-si, Gyeonggi-do 10408, Republic of Korea. 4. Neuro-oncology Clinic, National Cancer Center, Goyang, Republic of Korea.

Received: 6 December 2018 Accepted: 11 March 2019 Published online: 27 March 2019

**References**

1. Chamberlain MC. Neoplastic meningitis. Oncologist. 2008;13:967–77.
2. Gwak HS, Lee SH, Park WS, et al. Recent advancements of treatment for leptomeningeal carcinomatosis. J Korean Neurosurg Soc. 2015;58:1–8.
3. Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012;7:382–5.
4. Tetef ML, Margolin KA, Doroshov JH, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol. 2000;46:19–26.
5. Shapiro WR, Young DF, Mehta BM. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161–6.
6. Wassertrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49:759–72.
7. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer. 2004;40:2726–33.
8. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer. 1998;82:1756–63.
9. Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal metastases. J Neuro-Oncol. 1998;38:135–40.
10. Blasberg RG, Patlak CS, Shapiro WR. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep. 1977;61:633–41.
11. Jung TY, Chung WK, Oh U. The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases. Clin Neurol Neurosci. 2014;119:80–3.
12. Lin N, Dunn IF, Glantz M, et al. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. J Neurosurg. 2011;115:730–6.
13. Lee SH, Kong DS, Seol HL, et al. Ventriculoperitoneal shunt for hydrocephaus caused by central nervous system metastasis. J Neuro-Oncol. 2011;104:545–51.
14. Hoffman HJ, Hendrick EB, Humphreys RP. Metastasis via ventriculoperitoneal shunt in patients with medulloblastoma. J Neurosurg. 1976;44:562–6.
15. Menger RP, Connor DE Jr, Thakur JD, et al. A comparison of lumboperitoneal and ventriculoperitoneal shunting for idiopathic intracranial hypertension: an analysis of economic impact and complications using the Nationwide Inpatient Sample. Neurosurg Focus. 2014;37:E4.
16. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38:1–7.
17. Gwak HS, Joo J, Kim S, et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol. 2013;8:599–605.
18. Lokich J, Levine H, Nesser I. Malignancy-related hydrocephalus: clinical features and results of ventricular peritoneal shunt procedure in three patients. Ann J Clin Oncol. 1998;21:365–8.
19. Omuro AM, Lallana EC, Bitsky MH, et al. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology. 2005;64:625–7.
20. Mcgirt MJ, Woodworth G, Thomas G, et al. Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes. J Neurosurg. 2004;101:627–32.
21. Wilson TJ, Stettler WR Jr, Al-Holou WN, et al. Comparison of the accuracy of ventricular catheter placement using freehand placement, ultrasonic guidance, and stereotactic neuroradiology. J Neurosurg. 2013;119:66–70.
22. Lee L, King NK, Kumar D, et al. Use of programmable versus nonprogrammable shunts in the management of hydrocephalus secondary to aneurysmal subarachnoid hemorrhage: a retrospective study with cost-benefit analysis. J Neurosurg. 2014;121:899–903.
23. Karabatsou K, Quigley G, Buxton N, et al. Ventriculoperitoneal shunts: are the complications acceptable? Acta Neurochir. 2004;146:1193–7.
24. Berger MS, Baumeister B, Geyer JR, et al. The risks of metastases from shunting in children with primary central nervous system tumors. J Neurosurg. 1991;74:872–7.
25. Magitibay PM, Friedman JA, Rao RD, et al. Unusual presentation of adult metastatic peritoneal medulloblastoma associated with a ventriculoperitoneal shunt: a case study and review of the literature. Neuro-Oncology. 2003;5:217–20.
26. Eggenberger ER, Miller NR, Vitale S. Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Neurology. 1996;46:1524–30.
27. Spetzler RF, Wilton CB, Grollmus JM. Pseudotumorous lumboperitoneal shunt. Technical note. J Neurosurg. 1975;43:770–3.
28. Aoki N. Lumboperitoneal shunt: clinical applications, complications, and comparison with ventriculoperitoneal shunt. Neurosurgery. 1990;26:998–1003 discussion 1003–1004.

29. Toma AK, Dherijha M, Kitchen ND, et al. Use of lumboperitoneal shunts with the Strata NSC valve: a single-center experience. J Neurosurg. 2010;113:1304–8.

30. Nadkarni TD, Rekate HL, Wallace D. Concurrent use of a lumboperitoneal shunt with programmable valve and ventricular access device in the treatment of pseudotumor cerebri: review of 40 cases. J Neurosurg Pediatr. 2008;2:19–24.

31. Zhang XH, Wang XG, Piao YZ, et al. Lumboperitoneal shunt for the treatment of leptomeningeal metastasis. Med Hypotheses. 2015;84:506–8.